Mir Imran founded InCube Labs, a multi-disciplinary research lab, and InCube Ventures, a life sciences venture fund, to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. Mir began his career as a med-tech entrepreneur in the late 1970's and has founded numerous game-changing companies since those early days.
Over the decades, he has become one of the leading inventors and entrepreneurs in healthcare. Mir now holds more than 200 issued patents and is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator, a device sold to Eli Lilly and is now part of Guidant. Additionally, Mir has invented a number of breakthrough devices that set new standards of care for their industries.
As an entrepreneur, Mir has founded more than 20 medical device companies; 15 of his companies have seen "liquidity events" (IPO/Acquisition). Mir currently holds board seats with Bodymedia, Corhythm, eGeen, Entrack, Fe3, Intrapace, Modulus, Neurolink, NFocus, and Spinal Modulation. Mir is also Chairman and CEO of InCube Labs and Modulus Inc., a manufacturing and product development company focused on the medical device market. For more information on Mir and his companies, go to www.incubelabs.com and www.modulusinc.com.
Andrew is an investor and entrepreneur with two decades of experience building, restructuring and acquiring companies in life sciences. A founding member of InCube's venture fund, Andrew co-founded VentureHealth to democratize investing for accredited investors who have a passion for improving patient outcomes, and do not have access to venture capital deals.
Prior to his current roles, Andrew served as a Partner in the Halo Funds, where he completed a Kauffman Fellowship and led investments in a portfolio of life science firms. These investments included Intrapace (obesity), Penumbra (ischemic stroke), Safeview (security), Sonoma Orthopedic Products (bone repair), SwitchGear Genomics (gene regulation) & Spinal Modulation (pain management). Andrew has also been an active angel investor in a broader variety of ventures.
Earlier in his career, Andrew served as Chief Commercial Officer for Operon Technologies. During his tenure there, Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to $40M in two years, and helped to negotiate a sale of the business to QIAGEN for $150M. He subsequently acquired a company in Japan for QIAGEN, and restructured it into the company's global operations. Prior to Operon, Andrew held several roles in research operations at Genentech, Inc., where he managed $200M of protein therapeutic production and optimized cell lines for expression. Andrew has also co-founded a gene design business in agricultural biotechnology (Glucazyme), launched a company in microfludics (Innovadyne), sat on a wide range of boards, and developed strategies for healthcare firms as a consultant with Deloitte & Touche.
Andrew holds a Masters of Business Administration from Harvard University and a Bachelor's from the University of California at Berkeley.
Talat co-founded VentureHealth because he is passionate about improving the supply of capital for healthcare innovations, while also creating opportunities for accredited physician investors to leverage their resources and expertise.
He has worked in the venture capital industry since 2005, when he joined The Angels’ Forum (TAF) and The Halo Fund. During his time at TAF, he managed the deal flow process and worked with tech, consumer and healthcare startups to refine their business plans and presentations. Leveraging his background in medical device software development, Talat continues to serve a similar role at InCube Ventures, evaluating early stage technologies in the healthcare sector.
During his time at both TAF and InCube Ventures, Talat was struck by the challenges facing healthcare entrepreneurs in funding their vision for improving clinical outcomes. Limited access to early stage capital in the healthcare sector, compared to the tech and consumer markets, is particularly striking given the percent of the national GDP spent on healthcare-related products and services each year.
A software developer by training, Talat has over 10 years of experiencing designing, developing and marketing web applications. He has architected, launched and scaled apps for startups and pre-IPO companies alike, using cloud-based technologies, SEO, SEM and social media marketing.
Talat holds a bachelor’s degree in computer science from the University of California, Santa Cruz.
Mar brings a passion for breakthrough innovations and healthcare to VentureHealth. She has spent her career in life sciences, most recently as a leader in sales and marketing for Johnson & Johnson. When Mar heard about VentureHealth, she fell in love with the opportunity to help investors and entrepreneurs dramatically improve the lives of patients. Intellectually curious, she loves building VentureHealth from the ground up with a proven and successful team.
Mar received her International MBA from ADM Business School - UC Riverside, and holds an additional degree in Business Management from Universidad San Pablo CEU and Leeds Metropolitan University. She recently relocated to California after living in Spain, the United Kingdom and Australia - and Silicon Valley already feels like home.
Stephanie brings 20 years of marketing, communications and business management experience to VentureHealth. Stephanie serves as Vice President of Communications supporting our firm as well as our portfolio companies. Stephanie is also the Vice President, Business Development and Marketing for InCube Labs, the life science R&D lab led by Mir Imran focused on developing and commercializing breakthrough healthcare innovations. Prior to joining InCube, Stephanie was a founding member and EVP of Greenough Communications, a national marketing services firm that served a range of industries from technology to life sciences. Stephanie holds a B.A. in English from The College of the Holy Cross.